Satellos Bioscience Inc.

TSX:MSCL.TO

Biotechnology

Healthcare
$8.62 +0.12%

+$0.01 today

Market cap
$182.89M
Beta
1.17
P/E (TTM)
-1.8
EPS (TTM)
-$0.32
52W Low $6.36High $18.98

Volume 0.01M

Average 0.02M

MSCL.TO Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Satellos Bioscience Inc.TSX: MSCL.TO

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures turns negative

Q1 FY2026 capital expenditures was -$3.94K, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$9.93K. Over 3 fiscal years it compounded at +26.7% a year.

Context

  • Capital expenditures grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly capital expenditures holds near -$3.94K or moves back toward the trailing-twelve-month quarterly average of -$2.48K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.94K-67612.9% QoQ
Last fiscal yearDec 2025
-$6.1K+1.7% YoY
LTMMar 2026
-$9.93K— YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+1.7%——
3-year CAGR+26.7%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

Mixed currencies · from the cash flow

Latest · FY2025
(6.1K) USD
Year-over-year change
—

Capital Expenditures vs competitors

How MSCL.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Over three fiscal years its annual growth of +26.7% compares with a peer median of -64.5%.
MSCL.TO Competitors
Capital Expenditures for MSCL.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026CA$60.13K CAD+102.0%-31.1%—
MSCL.TOSatellos Bioscience Inc.LTM Mar 2026$9.93K USD—+26.7%—
SVA.TOSernova Corp.LTM Apr 2026CA$4 CAD-200.0%-97.9%—
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$0 CAD+100.0%——
Peer median (excluding MSCL.TO) —+100.0%-64.5%—

Competitors are the stored peer set for MSCL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · CAD
FY2024
Dec 2024 · CAD
FY2025
Dec 2025 · USD
Net Income(15.51M)(11.32M)(15.89M)(28.1M)(25.31M)
Depreciation & Amortization165.69K337K7K20K4K
Deferred Income Tax00000
Stock-Based Compensation971.53K1.44M2.17M2.11M3.24M
Change in Working Capital(485.64K)991K369K(1.03M)(1.5M)
Accounts Receivables(67.4K)267.55K(323K)(43K)66.14K
Inventory00000
Accounts Payables(390.47K)726.11K000
Other Working Capital(27.77K)(1.93K)692K(982K)(1.57M)
Other Non-Cash Items9.82M2.91M(1.07M)2.02M(435.77K)
Operating Cash Flow(5.03M)(5.78M)(14.5M)(24.98M)(24.01M)
Capital Expenditures(7.25K)(3K)(18K)(6K)(6.1K)
Acquisitions (Net)1.75M0000
Purchases of Investments00(17.52M)(37.34M)(23.78M)
Sales of Investments00043.68M14.2M
Other Investing Activities00000
Investing Cash Flow1.74M(3K)(17.54M)6.34M(9.58M)
Debt Repayment186.57K0(284K)00
Common Stock Issued7.08M2.78M32.46M42.8M2.28M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities185.46K018.85M10.68M0
Financing Cash Flow7.45M2.78M51.03M53.49M2.28M
Effect of Forex Changes(1.44K)(76K)1.15M744K(890.45K)
Net Change in Cash4.15M(2.95M)20.14M35.59M(32.2M)
Free Cash Flow(5.04M)(5.79M)(14.52M)(24.98M)(24.02M)

Satellos Bioscience Inc.

TSX:MSCL.TO

Intrinsic Alpha fair value

Locked

Current Price

$8.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.